Prevacid Iv is a drug owned by Takeda Pharmaceuticals North America Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 17, 2022. Details of Prevacid Iv's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7396841 (Pediatric) | Injections |
Feb, 2022
(3 years ago) |
Expired
|
| US7396841 | Injections |
Aug, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prevacid Iv's patents.
Latest Legal Activities on Prevacid Iv's Patents
Given below is the list of recent legal activities going on the following patents of Prevacid Iv.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 05 Aug, 2016 | US7396841 |
| Post Issue Communication - Certificate of Correction | 05 Feb, 2009 | US7396841 |
| Patent Issue Date Used in PTA Calculation Critical | 08 Jul, 2008 | US7396841 |
| Recordation of Patent Grant Mailed Critical | 08 Jul, 2008 | US7396841 |
| Issue Notification Mailed Critical | 18 Jun, 2008 | US7396841 |
| Dispatch to FDC | 06 Jun, 2008 | US7396841 |
| Application Is Considered Ready for Issue Critical | 20 May, 2008 | US7396841 |
| Issue Fee Payment Received Critical | 15 May, 2008 | US7396841 |
| Issue Fee Payment Verified Critical | 15 May, 2008 | US7396841 |
| Mail Notice of Allowance Critical | 19 Mar, 2008 | US7396841 |
US patents provide insights into the exclusivity only within the United States, but Prevacid Iv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prevacid Iv's family patents as well as insights into ongoing legal events on those patents.
Prevacid Iv's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Prevacid Iv's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 17, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prevacid Iv Generic API suppliers:
Lansoprazole is the generic name for the brand Prevacid Iv. 27 different companies have already filed for the generic of Prevacid Iv, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Prevacid Iv's generic
Alternative Brands for Prevacid Iv
Prevacid Iv which is used for short-term treatment of all grades of erosive esophagitis when oral formulations are not feasible., has several other brand drugs using the same active ingredient (Lansoprazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Dexcel |
| |||
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lansoprazole, Prevacid Iv's active ingredient. Check the complete list of approved generic manufacturers for Prevacid Iv
About Prevacid Iv
Prevacid Iv is a drug owned by Takeda Pharmaceuticals North America Inc. It is used for short-term treatment of all grades of erosive esophagitis when oral formulations are not feasible. Prevacid Iv uses Lansoprazole as an active ingredient. Prevacid Iv was launched by Takeda Pharms Na in 2004.
Approval Date:
Prevacid Iv was approved by FDA for market use on 27 May, 2004.
Active Ingredient:
Prevacid Iv uses Lansoprazole as the active ingredient. Check out other Drugs and Companies using Lansoprazole ingredient
Treatment:
Prevacid Iv is used for short-term treatment of all grades of erosive esophagitis when oral formulations are not feasible.
Dosage:
Prevacid Iv is available in injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INTRAVENOUS |